Carfilzomib

Red

Brand Name(s):Kyprolis

Indication:Multiple Myeloma

Rationale:1,2,3

Considered:Nov-15

Review Date:Jan-25

Comments:
Carfilzomib (Kyprolis BLACK TRIANGLE DRUG): risk of reactivation of hepatitis B virus-NOV 19
Establish hepatitis B status before initiating carfilzomib and in patients with unknown hepatitis B virus serology who are already being treated with carfilzomib
LINK; https://www.gov.uk/drug-safety-update/carfilzomib-kyprolis-risk-of-reactivation-of-hepatitis-b-virus

Drug safety update; Carfilzomib (KyprolisBLACK TRIANGLE DRUG): reminder of risk of potentially fatal cardiac events
Anti-cancer therapy with carfilzomib has been associated with cases of cardiac arrest, cardiac failure, and myocardial infarction, including in patients without pre-existing cardiac disorders.